Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas Journal Article
| Authors: | Chen, Y. T.; Chadburn, A.; Lee, P.; Hsu, M.; Ritter, E.; Chiu, A.; Gnjatic, S.; Pfreundschuh, M.; Knowles, D. M.; Old, L. J. |
| Article Title: | Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas |
| Abstract: | We have shown previously that cancer/testis (CT) antigen, CT45, is expressed in various epithelial cancers at a frequency of <5% to ∼35%. In this study, the protein expression of CT45 was examined in non-Hodgkin B-cell lymphomas and classical Hodgkin lymphoma by immunohistochemical analysis. Serological response to CT45 was also evaluated by ELISA using CT45 recombinant protein and sera frompatients with Hodgkin lymphoma. None of the 80 low-grade B-cell lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, andmantle cell lymphoma, expressed CT45. In comparison, CT45 was expressed in 28 of 126 (22%) diffuse large B-cell lymphomas (DLBCL). A remarkably high percentage (42/72, 58%) of classical Hodgkin lymphoma contained CT45-positive Reed-Sternberg cells. Nodular sclerosis and mixedcellularity subtypes had similar frequency of CT45 expression, but most EBV-positive cases were CT45 negative. Gray-zone lymphoma (caseswith features of both DLBCL and classical Hodgkin lymphoma) also showed frequent (64%) CT45 expression. Evaluation of reactive lymphoid tissues showed scattered CT45-positive lymphocytes in a single case of florid follicular hyperplasia, raising the possibility that this case was an evolvingmalignancy. Despite frequent CT45 expression, only 1 of 67 Hodgkin lymphoma patients had detectable anti-CT45 antibodies in the serum, suggesting that the immune response to CT45 may be suppressed. In conclusion, classical Hodgkin lymphomahas thehighest frequencyofCT45expressionamongallmalignancies tested to date, the frequency of CT45 expression in DLBCL is similar to that seen in epithelial cancers, and low-grade non-Hodgkin B-cell lymphomas do not express CT45. |
| Keywords: | immunohistochemistry; adult; controlled study; human tissue; protein expression; unclassified drug; human cell; major clinical study; cancer grading; mantle cell lymphoma; tumor antigen; enzyme linked immunosorbent assay; hodgkin disease; in situ hybridization; b cell lymphoma; lymphoma, b-cell; nonhodgkin lymphoma; immune response; immunotherapy; antigens, neoplasm; cancer testis antigen; immunogenicity; recombinant protein; immunophenotyping; large cell lymphoma; cancer testis antigen ct45; enzyme-linked immunosorbent assay; lymphoid tissue; chronic lymphatic leukemia; follicular lymphoma; serology; epstein barr virus; lymphocytoma; classical hodgkin lymphoma; reed sternberg cell; reed-sternberg cells; lymphoid hyperplasia; tumor immunology; cancer vaccine target; gray zone lymphoma; mixed cellularity hodgkin lymphoma; nodular sclerosis hodgkin lymphoma; human herpesvirus 4 |
| Journal Title: | Proceedings of the National Academy of Sciences of the United States of America |
| Volume: | 107 |
| Issue: | 7 |
| ISSN: | 0027-8424 |
| Publisher: | National Academy of Sciences |
| Date Published: | 2010-02-16 |
| Start Page: | 3093 |
| End Page: | 3098 |
| Language: | English |
| DOI: | 10.1073/pnas.0915050107 |
| PUBMED: | 20133697 |
| PROVIDER: | scopus |
| PMCID: | PMC2840360 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: PNASA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work